Literature DB >> 24460254

MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27.

Zhong-Qing Cao1, Zan Shen, Wei-Yi Huang.   

Abstract

MicroRNAs have been demonstrated to regulate proliferation and apoptosis in many types of cancers, but biological functions in osteosarcomas remain relatively unknown. Here, we found expression of miR-802 to be up-regulated in osteosarcoma tissues in comparison with adjacent normal tissues. Enforced expression of miR-802 was able to promote cell proliferation in U2OS and MG63 cells, while miR-802 antisense oligonucleotides (antisense miR-802) inhibited cell proliferation. At the molecular level, our results further revealed that expression of p27, a negative cell-cycle regulator, was negatively regulated by miR-802. Therefore, the data reported here indicate that miR-802 is an important regulator in osteosarcoma, our findings contributing to a better understanding of important mis-regulated miRNAs in this tumour type.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24460254     DOI: 10.7314/apjcp.2013.14.12.7081

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  23 in total

1.  MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.

Authors:  Xiaozhen Wu; Zuode Gong; Lanying Sun; Long Ma; Qibao Wang
Journal:  Cell Prolif       Date:  2017-03-20       Impact factor: 6.831

2.  A microRNA cluster (let-7c, miRNA-99a, miRNA-125b, miRNA-155 and miRNA-802) encoded at chr21q21.1-chr21q21.3 and the phenotypic diversity of Down's syndrome (DS; trisomy 21).

Authors:  Yuhai Zhao; Vivian Jaber; Maire E Percy; Walter J Lukiw
Journal:  J Nat Sci       Date:  2017-09

3.  Demethylation of microRNA-142 induced by demethylation agents plays a suppressive role in osteosarcoma cells.

Authors:  Muliang Ding; Jianzhong Hu; Jiangdong Ni; Zhonghui Zheng; Deye Song; Junjie Wang
Journal:  Oncol Lett       Date:  2015-03-13       Impact factor: 2.967

4.  Chromosome 21-Encoded microRNAs (mRNAs): Impact on Down's Syndrome and Trisomy-21 Linked Disease.

Authors:  P N Alexandrov; M E Percy; Walter J Lukiw
Journal:  Cell Mol Neurobiol       Date:  2017-07-07       Impact factor: 5.046

5.  Long noncoding RNA TRG-AS1 protects against glucocorticoid-induced osteoporosis in a rat model by regulating miR-802-mediated CAB39/AMPK/SIRT-1/NF-κB axis.

Authors:  Wen Liu; Guojuan Li; Jing Li; Wei Chen
Journal:  Hum Cell       Date:  2022-07-07       Impact factor: 4.374

6.  Effect of Anti-Osteoporotic Treatments on Circulating and Bone MicroRNA Patterns in Osteopenic ZDF Rats.

Authors:  David Carro Vázquez; Lejla Emini; Martina Rauner; Christine Hofbauer; Johannes Grillari; Andreas B Diendorfer; Richard Eastell; Lorenz C Hofbauer; Matthias Hackl
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

7.  A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer.

Authors:  James Saller; Kun Jiang; Yin Xiong; Sean J Yoder; Kevin Neill; Jose M Pimiento; Luis Pena; F Scott Corbett; Anthony Magliocco; Domenico Coppola
Journal:  Dig Dis Sci       Date:  2021-03-13       Impact factor: 3.199

8.  MicroRNA-802 promotes the progression of osteosarcoma through targeting p27 and activating PI3K/AKT pathway.

Authors:  L F Gao; S Jia; Q M Zhang; Y F Xia; C J Li; Y H Li
Journal:  Clin Transl Oncol       Date:  2021-07-27       Impact factor: 3.405

9.  MicroRNA‑20a promotes the proliferation and cell cycle of human osteosarcoma cells by suppressing early growth response 2 expression.

Authors:  Wenkun Zhuo; Weiming Ge; Guolin Meng; Shuaijun Jia; Xiang Zhou; Jian Liu
Journal:  Mol Med Rep       Date:  2015-07-20       Impact factor: 2.952

10.  Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer.

Authors:  Sören Müller; Susanne Raulefs; Philipp Bruns; Fabian Afonso-Grunz; Anne Plötner; Rolf Thermann; Carsten Jäger; Anna Melissa Schlitter; Bo Kong; Ivonne Regel; W Kurt Roth; Björn Rotter; Klaus Hoffmeier; Günter Kahl; Ina Koch; Fabian J Theis; Jörg Kleeff; Peter Winter; Christoph W Michalski
Journal:  Mol Cancer       Date:  2015-04-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.